Tech Company Financing Transactions
Sage Therapeutics Funding Round
Third Rock Ventures and private investors joined a $35 million Series A funding round for Sage Therapeutics. The round was announced by the company on 10/18/2011.
Transaction Overview
Company Name
Announced On
10/18/2011
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Third Rock Ventures (Lead Investor) (Kevin Starr)
Proceeds Purpose
The company will use the Series A to Accelerate Treatments for CNS Conditions; Expects to Launch First of Several Clinical Programs in 2012.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
215 1st St.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Sage Therapeutics' (NASDAQ: SAGE) mission is to make life better for patients with nervous systems diseases by discovering, developing, and delivering important new medicines to the market.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Jonas
Chief Financial Officer
Kimi Iguchi
Chief Medical Officer
Stephen Kanes
Chief Scientific Officer
Albert Robichaud
VP - Bus. Development
Michael Cloonan
VP - General Counsel
Anne Marie
VP - Human Resources
Erin Lanciani
VP - Operations
Heinrich Schlieker
VP - R & D
James Doherty
VP - Regulatory Affairs
Amy Schacterle
Browse more venture capital transactions:
Prev: 10/18/2011: BillGuard venture capital transaction
Next: 10/19/2011: GroSocial venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs